The exclusive agreement also includes development, regulatory, and commercialization milestone payments based on the successful outcome
First published clinical trial using live biotherapeutic candidate in Covid-19 patients suggests role in improving outcomes
This acquisition marks Max Healthcare's entry into Lucknow
his marks the 12th formulation facility under Akums, and the second in Baddi, a strategic move with an aim to enhance Akums’ manufacturing capabilities.
Dr. Reddy's will make a US$ 7.5 million upfront payment to Coya
Carmot Therapeutics’s R&D portfolio of clinical stage incretins has great potential to treat obesity, diabetes and potentially other diseases
The company also organised sensitization workshops for its employees aimed at increasing awareness of challenges faced by hearing-impaired individuals
Accelerating FDA submission and confirming potential to become first approved biologic for this serious disease
Both the India and GCC entities will be operated by separate dedicated management teams
Subscribe To Our Newsletter & Stay Updated
